OCon behalf of the PRISONAFLD Study Group Collaborators
on behalf of the PRISONAFLD Study Group Collaborators
+6
Background and Aims: The prevalence of chronic non-communicable diseases, particularly metabolic syndrome (MetS), has increased among the prison population. Nevertheless, we have limited data on metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of this syndrome. We aimed to investigate the prevalence and risk factors of MASLD and MASLD-associated liver fibrosis in the penitentiary population in Catalonia, Spain. Method: A cross-sectional observational study involving eight penitentiary centers. Participants had at least one metabolic disorder and were at a closed-regimen penitentiary. Individuals with concomitant liver diseases and/or alcohol risk consumption were excluded. Significant fibrosis and MASLD were defined as liver stiffness ≥8 kPa and a controlled attenuation parameter ≥275 dB/m by vibration-controlled transient elastography (VCTE), respectively. After exclusions, metabolic inmates with VCTE were analyzed. Logistic regression analysis was performed to identify predictors of MASLD and MASLD-associated significant fibrosis. Results: Out of the 4338 inmates studied, 1290 (29.7%) had metabolic disorders, and 646 (14.9%) underwent VCTE. The mean age was 48.0 years (SD 12.1), and 89.5% were male. MASLD prevalence was 33.9%. Significant fibrosis and MASLD-associated significant fibrosis were found in 16.4% and 9.4% of inmates, respectively. In the multivariate analysis, T2D, waist circumference, MetS, and higher ALT values were identified as independent risk factors for MASLD and MASLD-associated significant fibrosis amongst the prison population. Conclusions: Metabolic disorders including MASLD are highly prevalent among inmates. The prevalence of significant fibrosis seems notably higher than that of the general population, underscoring the need for targeted screening programs and therapeutic interventions in the incarcerated population.
Background: Whether patients with metabolic dysfunction–associated steatotic liver disease (MASLD) cirrhosis can achieve recompensation is still a subject of debate. This study aimed to evaluate the incidence and factors associated with recompensation in patients with decompensated MASLD cirrhosis. Methods: Cohort study across 4 university hospitals in Barcelona (Spain), enrolling individuals with MASLD cirrhosis at their initial decompensating event. Liver recompensation (Baveno VII) was defined as the absence of clinical decompensation after discontinuation of specific treatment, along with sustained improvement in liver function. Competing-risk regression models were used to identify predictors of recompensation. Results: Among 124 patients [mean age: 69 years (IQR 62–73), 53% males], 59% had obesity, 74% type 2 diabetes, 66% arterial hypertension, and 47% dyslipidemia. Most patients were Child–Pugh B (61%) with a median MELD-Na score of 11 (IQR 10–16). After a median follow-up of 2.1 years (IQR 0.97–4.53), the 2-year cumulative incidence of recompensation was 24%. Factors associated with recompensation included MELD-Na (aSHR 0.891 [95% CI 0.833–0.953]; p =0.001), albumin (aSHR 1.894 [95% CI 1.008–3.297]; p =0.024, ascites (aSHR 0.475, [95% CI 0.268–0.841]; p =0.011), and multiple decompensation (aSHR 0.151 [94% CI 0.033–0.698]; p =0.015) as a first decompensation event. Although a substantial proportion of patients initially achieved recompensation, this was frequently transient, and its apparent survival benefit did not persist after adjustment for liver function and accounting for time-dependence. Conclusions: Liver recompensation in MASLD cirrhosis occurs in 24% of patients within 2 years after first decompensation and is mainly dependent on basal liver function. However, frequent further decompensation limits its prognostic impact on survival.
Opportunistic case-finding of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) by leveraging integrated care pathways of type 2 diabetes
12 June 2026 in Clinical Gastroenterology and Hepatology
Steatotic liver disease (SLD) encompasses metabolic dysfunction-associated liver disease (MASLD), alcohol-related liver disease (ALD), and a mixed type (MetALD). We investigated the course of compensated advanced chronic liver disease (cACLD) across SLD subtypes, the impact of clinically significant portal hypertension (CSPH), and the role of non-invasive tests (NITs). This study included SLD patients with cACLD from 17 centers undergoing hepatic venous pressure gradient (HVPG) and NIT assessment through December 2023. Primary outcomes were first hepatic decompensation and liver-related mortality. Among 696 patients (ALD 22%, MetALD 20%, MASLD 58%), 94% had Child-Pugh A, and 60% had CSPH. Over a median follow-up of 3.8 years, 170 patients decompensated and 137 died (58% liver-related). The three-year cumulative decompensation incidence was highest in ALD (26%), followed by MetALD (21%) and MASLD (15%), yet differences were no longer significant after adjusting for age, sex, MELD, albumin, and HVPG. Similarly, liver-related mortality did not differ by SLD subtype in adjusted models. CSPH independently predicted decompensation across all subtypes. The ANTICIPATE-NASH model showed high and comparable diagnostic accuracy for CSPH across ALD, MetALD, and MASLD (AUROC 0.831-0.894). An ANTICIPATE-NASH probability ≥60% for ruling-in CSPH outperformed the original ANTICIPATE model in all subtypes and independently predicted decompensation with similar effect sizes (aSHR 2.57-2.71). Higher crude decompensation rates in ALD and MetALD reflect more severe liver disease at presentation, yet outcomes are comparable across the SLD spectrum after accounting for disease severity. ANTICIPATE-NASH accurately identifies CSPH across SLD subtypes, and both invasive and non-invasive measures of portal hypertension predict decompensation and liver-related death.